Total Funding
75
69
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
51098
IRLAB Therapeutics is a drug discovery and development company providing novel treatments for disorders of the brain.
- Kristina Torfgård: Chief Executive OfficerPast Role: Alzinova, Chief Executive Officer
- Nicholas Waters: Chief Executive Officer (CEO)
About the Company
IRLAB is a Swedish drug discovery and development company providing novel treatments for disorders of the brain.
IRLAB is engaged in programmes targeting core dysfunctions in Parkinson’s disease and dementias. IRLAB has identified, and is currently engaged in clinical development of, two novel compounds aimed at offering improved clinical benefit
for patients with Parkinson’s disease.
